EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $48.51, marking a -0.84% move from the previous day. This change lagged the S&P 500's daily loss of 0.18%. Elsewhere, the Dow saw ...

CRISPR Therapeutics AG (CRSP) closed the last trading session at $48.92, gaining 1.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

Given this risk, we thought we'd take a look at whether CRISPR Therapeutics (NASDAQ:CRSP) shareholders should be worried ...

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report).

Longer Term Trading Plans for CRSP. Buy CRSP near 40.82 target 52.08 stop loss @ 40.7 Details; The technical summary data ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other promising biotech stocks. Biotechnology stocks are known for their high risk ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...